EA201892707A1 - Способы и композиции для лечения целиакии, непереносимости глютена без целиакии и рефрактерной целиакии - Google Patents

Способы и композиции для лечения целиакии, непереносимости глютена без целиакии и рефрактерной целиакии

Info

Publication number
EA201892707A1
EA201892707A1 EA201892707A EA201892707A EA201892707A1 EA 201892707 A1 EA201892707 A1 EA 201892707A1 EA 201892707 A EA201892707 A EA 201892707A EA 201892707 A EA201892707 A EA 201892707A EA 201892707 A1 EA201892707 A1 EA 201892707A1
Authority
EA
Eurasian Patent Office
Prior art keywords
celiacia
treatment
refractory
gluten
methods
Prior art date
Application number
EA201892707A
Other languages
English (en)
Russian (ru)
Inventor
Франциско Леон
Уэйн Н. Тсуджи
Original Assignee
Амген Инк.
СЕЛИММЬЮН ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк., СЕЛИММЬЮН ЭлЭлСи filed Critical Амген Инк.
Publication of EA201892707A1 publication Critical patent/EA201892707A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
EA201892707A 2016-06-15 2016-06-15 Способы и композиции для лечения целиакии, непереносимости глютена без целиакии и рефрактерной целиакии EA201892707A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/037708 WO2017217985A1 (fr) 2016-06-15 2016-06-15 Procédés et compositions pour le traitement de la maladie cœliaque, sensibilité au gluten non cœliaque et maladie cœliaque réfractaire

Publications (1)

Publication Number Publication Date
EA201892707A1 true EA201892707A1 (ru) 2019-05-31

Family

ID=56292925

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892707A EA201892707A1 (ru) 2016-06-15 2016-06-15 Способы и композиции для лечения целиакии, непереносимости глютена без целиакии и рефрактерной целиакии

Country Status (11)

Country Link
EP (1) EP3472202A1 (fr)
JP (2) JP2019521981A (fr)
CN (1) CN109311972A (fr)
AR (1) AR108790A1 (fr)
AU (1) AU2016411388A1 (fr)
BR (1) BR112018076287A2 (fr)
CA (1) CA3020894A1 (fr)
EA (1) EA201892707A1 (fr)
MX (1) MX2018015363A (fr)
TW (2) TW201803591A (fr)
WO (1) WO2017217985A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019012570A8 (pt) * 2016-12-21 2023-01-24 Cephalon Inc Anticorpos que se ligam especificamente à il-15 humana e seus usos, composição, método in vitro para detecção de il-15 ou um complexo de il-15 e receptor de il-15-alfa, polinucleotídeo, vetor e método de produção do dito anticorpo
US20220008533A1 (en) * 2018-10-31 2022-01-13 Tiziana Life Sciences Plc Composition and methods of treating inflammatory and autoimmune diseases
AU2022325870A1 (en) 2021-08-12 2024-02-08 Amgen Inc. Antibody formulations
WO2024028448A1 (fr) 2022-08-04 2024-02-08 Calypso Biotech Sa Inhibiteurs d'il-15 utiles pour le traitement de la dermatite atopique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
ZA200506724B (en) * 2003-02-26 2007-03-28 Genmab As Human antibodies specific for interleukin 15 (IL-15)
AU2010208637A1 (en) * 2009-01-29 2011-08-04 Abbvie Inc. IL-1 binding proteins
WO2011031986A1 (fr) * 2009-09-10 2011-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health Dosages du récepteur soluble à il-15 alpha
EP2963057A1 (fr) * 2014-07-02 2016-01-06 Calypso Biotech SA Anticorps pour IL-15

Also Published As

Publication number Publication date
MX2018015363A (es) 2019-04-15
BR112018076287A2 (pt) 2019-03-26
EP3472202A1 (fr) 2019-04-24
CA3020894A1 (fr) 2017-12-21
CN109311972A (zh) 2019-02-05
WO2017217985A1 (fr) 2017-12-21
JP2019521981A (ja) 2019-08-08
TW202327653A (zh) 2023-07-16
AR108790A1 (es) 2018-09-26
JP2022001577A (ja) 2022-01-06
TW201803591A (zh) 2018-02-01
AU2016411388A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
CY1122184T1 (el) Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη
CY1121473T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
EA201790413A1 (ru) Антитела против tigit
EA201691114A1 (ru) Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
EA201692109A1 (ru) Варианты антител к фактору d и их применение
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
SA518391831B1 (ar) تركيبات وطرق لخفض تعبير البروتين تاو
EA201892707A1 (ru) Способы и композиции для лечения целиакии, непереносимости глютена без целиакии и рефрактерной целиакии
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA201791937A1 (ru) Противовоспалительные полипептиды
EA201691896A1 (ru) Соединения и способы их применения